Welcome!

News Feed Item

Spinal Stenosis Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 11, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Spinal Stenosis Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02280947/Spinal-Stenosis-Global-Clinical-Trials-Review-H2-2014.html

Spinal Stenosis Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Spinal Stenosis Global Clinical Trials Review, H2, 2014" provides data on the Spinal Stenosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Spinal Stenosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Spinal Stenosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Spinal Stenosis 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Spinal Stenosis to Central Nervous System Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Spinal Stenosis to Central Nervous System Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Spinal Stenosis 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Spinal Stenosis Therapeutics Clinical Trials 29
Prominent Drugs 30
Clinical Trial Profiles 31
Clinical Trial Overview of Top Companies 31
Sucampo Pharmaceuticals, Inc. 31
Clinical Trial Overview of Sucampo Pharmaceuticals, Inc. 31
Mesoblast Limited 32
Clinical Trial Overview of Mesoblast Limited 32
Zimmer Holdings, Inc. 33
Clinical Trial Overview of Zimmer Holdings, Inc. 33
United Therapeutics Corporation 34
Clinical Trial Overview of United Therapeutics Corporation 34
Nissan Chemical Industries, Ltd. 35
Clinical Trial Overview of Nissan Chemical Industries, Ltd. 35
LTT Bio-Pharma Co., Ltd. 36
Clinical Trial Overview of LTT Bio-Pharma Co., Ltd. 36
KT&G Corporation 37
Clinical Trial Overview of KT&G Corporation 37
Kaken Pharmaceutical Co., Ltd. 38
Clinical Trial Overview of Kaken Pharmaceutical Co., Ltd. 38
Biomet, Inc. 39
Clinical Trial Overview of Biomet, Inc. 39
Clinical Trial Overview of Top Institutes / Government 40
Seoul National University Hospital 40
Clinical Trial Overview of Seoul National University Hospital 40
Keio University 41
Clinical Trial Overview of Keio University 41
Hamamatsu University School of Medicine 42
Clinical Trial Overview of Hamamatsu University School of Medicine 42
University of Pittsburgh 43
Clinical Trial Overview of University of Pittsburgh 43
Vanderbilt University 44
Clinical Trial Overview of Vanderbilt University 44
Leiden University Medical Center 45
Clinical Trial Overview of Leiden University Medical Center 45
Yonsei University 46
Clinical Trial Overview of Yonsei University 46
Dartmouth-Hitchcock Medical Center 47
Clinical Trial Overview of Dartmouth-Hitchcock Medical Center 47
Emory University 48
Clinical Trial Overview of Emory University 48
Federal University of Sao Paulo 49
Clinical Trial Overview of Federal University of Sao Paulo 49
Five Key Clinical Profiles 50
Appendix 68
Abbreviations 68
Definitions 68
Research Methodology 69
Secondary Research 69
About GlobalData 70
Contact Us 70
Disclaimer 70
Source 70

List of Tables

Spinal Stenosis Therapeutics, Global, Clinical Trials by Region, 2014* 7
Spinal Stenosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Spinal Stenosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Spinal Stenosis Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 10
Spinal Stenosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Spinal Stenosis Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Spinal Stenosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Spinal Stenosis Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Spinal Stenosis to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Spinal Stenosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Spinal Stenosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Spinal Stenosis to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Spinal Stenosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Spinal Stenosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Spinal Stenosis Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Spinal Stenosis Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Spinal Stenosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Spinal Stenosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Spinal Stenosis Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Spinal Stenosis Therapeutics, Global, Terminated Clinical Trials, 2014* 25
Spinal Stenosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Spinal Stenosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 27
Spinal Stenosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Spinal Stenosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Spinal Stenosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Sucampo Pharmaceuticals, Inc., 2014* 31
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Mesoblast Limited, 2014* 32
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Zimmer Holdings, Inc., 2014* 33
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by United Therapeutics Corporation, 2014* 34
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Nissan Chemical Industries, Ltd., 2014* 35
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by LTT Bio-Pharma Co., Ltd., 2014* 36
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by KT&G Corporation, 2014* 37
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Kaken Pharmaceutical Co., Ltd., 2014* 38
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Biomet, Inc., 2014* 39
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Seoul National University Hospital, 2014* 40
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Keio University, 2014* 41
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Hamamatsu University School of Medicine, 2014* 42
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Pittsburgh, 2014* 43
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Vanderbilt University, 2014* 44
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Leiden University Medical Center, 2014* 45
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Yonsei University, 2014* 46
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Dartmouth-Hitchcock Medical Center, 2014* 47
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Emory University, 2014* 48
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Federal University of Sao Paulo, 2014* 49

List of Figures

Spinal Stenosis Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Spinal Stenosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Spinal Stenosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Spinal Stenosis Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 10
Spinal Stenosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Spinal Stenosis Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Proportion of Spinal Stenosis to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Spinal Stenosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Spinal Stenosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Spinal Stenosis to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Spinal Stenosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Spinal Stenosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Spinal Stenosis Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Spinal Stenosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Spinal Stenosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Spinal Stenosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Spinal Stenosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Spinal Stenosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 27
Spinal Stenosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Spinal Stenosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Spinal Stenosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
GlobalData Methodology 69


To order this report: Spinal Stenosis Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02280947/Spinal-Stenosis-Global-Clinical-Trials-Review-H2-2014.html



__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Organizations planning enterprise data center consolidation and modernization projects are faced with a challenging, costly reality. Requirements to deploy modern, cloud-native applications simultaneously with traditional client/server applications are almost impossible to achieve with hardware-centric enterprise infrastructure. Compute and network infrastructure are fast moving down a software-defined path, but storage has been a laggard. Until now.
"DevOps is set to be one of the most profound disruptions to hit IT in decades," said Andi Mann. "It is a natural extension of cloud computing, and I have seen both firsthand and in independent research the fantastic results DevOps delivers. So I am excited to help the great team at @DevOpsSUMMIT and CloudEXPO tell the world how they can leverage this emerging disruptive trend."
Adding public cloud resources to an existing application can be a daunting process. The tools that you currently use to manage the software and hardware outside the cloud aren’t always the best tools to efficiently grow into the cloud. All of the major configuration management tools have cloud orchestration plugins that can be leveraged, but there are also cloud-native tools that can dramatically improve the efficiency of managing your application lifecycle. In his session at 18th Cloud Expo, ...
Transformation Abstract Encryption and privacy in the cloud is a daunting yet essential task for both security practitioners and application developers, especially as applications continue moving to the cloud at an exponential rate. What are some best practices and processes for enterprises to follow that balance both security and ease of use requirements? What technologies are available to empower enterprises with code, data and key protection from cloud providers, system administrators, inside...
With the proliferation of both SQL and NoSQL databases, organizations can now target specific fit-for-purpose database tools for their different application needs regarding scalability, ease of use, ACID support, etc. Platform as a Service offerings make this even easier now, enabling developers to roll out their own database infrastructure in minutes with minimal management overhead. However, this same amount of flexibility also comes with the challenges of picking the right tool, on the right ...
In his session at 21st Cloud Expo, Raju Shreewastava, founder of Big Data Trunk, provided a fun and simple way to introduce Machine Leaning to anyone and everyone. He solved a machine learning problem and demonstrated an easy way to be able to do machine learning without even coding. Raju Shreewastava is the founder of Big Data Trunk (www.BigDataTrunk.com), a Big Data Training and consulting firm with offices in the United States. He previously led the data warehouse/business intelligence and Bi...
Nicolas Fierro is CEO of MIMIR Blockchain Solutions. He is a programmer, technologist, and operations dev who has worked with Ethereum and blockchain since 2014. His knowledge in blockchain dates to when he performed dev ops services to the Ethereum Foundation as one the privileged few developers to work with the original core team in Switzerland.
Contextual Analytics of various threat data provides a deeper understanding of a given threat and enables identification of unknown threat vectors. In his session at @ThingsExpo, David Dufour, Head of Security Architecture, IoT, Webroot, Inc., discussed how through the use of Big Data analytics and deep data correlation across different threat types, it is possible to gain a better understanding of where, how and to what level of danger a malicious actor poses to an organization, and to determin...
Cloud-enabled transformation has evolved from cost saving measure to business innovation strategy -- one that combines the cloud with cognitive capabilities to drive market disruption. Learn how you can achieve the insight and agility you need to gain a competitive advantage. Industry-acclaimed CTO and cloud expert, Shankar Kalyana presents. Only the most exceptional IBMers are appointed with the rare distinction of IBM Fellow, the highest technical honor in the company. Shankar has also receive...
Digital Transformation and Disruption, Amazon Style - What You Can Learn. Chris Kocher is a co-founder of Grey Heron, a management and strategic marketing consulting firm. He has 25+ years in both strategic and hands-on operating experience helping executives and investors build revenues and shareholder value. He has consulted with over 130 companies on innovating with new business models, product strategies and monetization. Chris has held management positions at HP and Symantec in addition to ...
Traditional IT, great for stable systems of record, is struggling to cope with newer, agile systems of engagement requirements coming straight from the business. In his session at 18th Cloud Expo, William Morrish, General Manager of Product Sales at Interoute, will outline ways of exploiting new architectures to enable both systems and building them to support your existing platforms, with an eye for the future. Technologies such as Docker and the hyper-convergence of computing, networking and...
Today, we have more data to manage than ever. We also have better algorithms that help us access our data faster. Cloud is the driving force behind many of the data warehouse advancements we have enjoyed in recent years. But what are the best practices for storing data in the cloud for machine learning and data science applications?
"MobiDev is a Ukraine-based software development company. We do mobile development, and we're specialists in that. But we do full stack software development for entrepreneurs, for emerging companies, and for enterprise ventures," explained Alan Winters, U.S. Head of Business Development at MobiDev, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
As Cybric's Chief Technology Officer, Mike D. Kail is responsible for the strategic vision and technical direction of the platform. Prior to founding Cybric, Mike was Yahoo's CIO and SVP of Infrastructure, where he led the IT and Data Center functions for the company. He has more than 24 years of IT Operations experience with a focus on highly-scalable architectures.
Cloud computing delivers on-demand resources that provide businesses with flexibility and cost-savings. The challenge in moving workloads to the cloud has been the cost and complexity of ensuring the initial and ongoing security and regulatory (PCI, HIPAA, FFIEC) compliance across private and public clouds. Manual security compliance is slow, prone to human error, and represents over 50% of the cost of managing cloud applications. Determining how to automate cloud security compliance is critical...